Jan 10 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:
RHYTHM PHARMACEUTICALS INC: IMCIVREE NET REVENUE FY24 EXPECTED TO BE ABOUT $130 MILLION
RHYTHM PHARMACEUTICALS: ON TRACK TO REPORT TOPLINE DATA FROM GLOBAL PHASE 3 TRIAL EVALUATING SETMELANOTIDE IN ACQUIRED HYPOTHALAMIC OBESITY IN H1 2025
RHYTHM PHARMACEUTICALS: PLAN TO INITIATE NEW PHASE 2 TRIAL EXPLORING SETMELANOTIDE IN PRADER-WILLI SYNDROME
Further company coverage: RYTM.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.